Tag : Therapeutics

CCT Impact

NAVIGESIA: Personalized Medicine Data Platform for Clinical Neurosciences and Emerging Therapeutics (Cannabis, Psychedelics, Nootropics)

CCT IMPACT Agent
NAVIGESIA, a personalized medicine software company expands their real-world data tools for clinical neurology and psychology industries, supporting patient management with psychoactive compounds: cannabis, psychedelics, nootropics. The NAVIGESIA platform helps teams collect quantifiable information for the purposes of building the best real-world representations for clinical stories and journeys. From baseline assessments to......
CCT Impact

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

CCT IMPACT Agent
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the “MOU”) regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic......
CCT Impact

Prima Closes $9.2 Million Seed Plus Financing to Accelerate Growth as Top Player in Plant Therapeutics and Cannabinoid Sciences

CCT IMPACT Agent
 The Uplifters’ Prima, PBC (“Prima“) the award-winning, purpose-driven brand focused on efficacy-driven and science-backed plant therapeutics and cannabinoids, today announced the close of a $9.2 million Seed Plus financing led by leading institutional venture firms Greycroft, H Ventures, Defy, and Lerer Hippeau, with notable participation from Adam Zeplain (mark vc), Global Founders Capital, Emerald Health, One Gun, and Purple Arch Ventures. Prima......
CCT Impact

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program

CCT IMPACT Agent
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) (“SpringWorks”) today announced that Jazz Pharmaceuticals Ireland Limited (“Jazz”) and SpringWorks have entered into an asset purchase and exclusive license agreement under which Jazz has acquired SpringWorks’ fatty acid amide hydrolase (“FAAH”) inhibitor program including PF-04457845. Jazz will initially focus on developing......
CCT Impact

Global Market Landscape for the Endocannabinoid System Targeted Therapeutics Market 2020 – Development Pipeline for Drugs Targeting Endocannabinoid System

CCT IMPACT Agent
The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. Chronic conditions, such as arthritis, cancer, diabetes, and heart disease are known to affect approximately 133 million Americans, representing over 40% of the total US population. This number is projected to grow to 157 million by the end of 2020.......